As the next generation of cancer drugs arrives, how many U.S. patients will be able to afford them?
That's a major question at UnitedHealthcare, which insures more than 40 million U.S. residents for their medical expenses. "The cost of established cancer drugs is increasing by 7% to 10% a year," says Lee Newcomer, MD, senior vice president of oncology services at the Minnetonka, MN, company. "Additionally, if a new-generation agent at $100,000 a year replaces old agents at $7,000, you can imagine the kinds of infl ation rates we're seeing." While it's diffi cult to get a handle on the accelerating cost of drugs, some oncologists point out that the 13 cancer drugs approved by the U.S. Food and Drug Administration (FDA) in 2012 all cost more than $5,900 per month.
Such pricing is strongly driven by federal and state drug policies, comments Scott Ramsey, MD, PhD, a health economist and oncologist who directs the Hutchinson Institute for Cancer Outcomes Research at Fred Hutchinson Cancer Research Center in Seattle, WA.
One cost driver is that the Centers for Medicare and Medicaid Services, which cover about half the nation's spending on cancer treatments, do not negotiate cancer drug prices with manufacturers. A related issue is that oncologists typically draw a substantial portion of their income from reimbursements for drugs at Medicare's average-sales-price-plus-6% rate, Ramsey says. (The 6% rate has been cut to 4.2% this year under the federal budget sequestration clampdown.) A higher price tag for a drug thus increases the income to oncologists when they prescribe it under the price-plus reimbursement system, creating a strong incentive for companies to set high prices.
Another major factor is that "most states now have mandatory coverage rules for new approved oncologic drugs; insurance companies are forced to cover them no matter what," Ramsey adds.
Given the effect of these state rules on insurers, "we're not allowed to make a value decision," Newcomer emphasizes. "There is no price regulation at all, and insurers don't have any negotiating ability. The only way we can make this work is to pass the cost on to patients as higher premiums and copays."
In turn, drug expenses are a major contributor to the diffi culties cancer patients face in paying their medical bills, says Ramsey, who headed a study showing that people with cancer in Washington State are more than twice as likely to declare bankruptcy as those unaffected by the disease (Health Aff 2013; 32:1143-52) . "There's immediate harm that's happening right now with our patients," declares Yousuf Zafar, MD, an oncologist at Duke Cancer Institute and assistant professor of medicine at Duke University School of Medicine in Durham, NC. "Many of them mention the diffi culties they are having with drug costs and other treatment-related costs, despite being insured. This fi nancial toxicity is an aspect of care that we're not addressing appropriately."
NOT COMPETING ON COST-EFFECTIVENESS
Throughout U.S. healthcare, many costs are not driven primarily by open market competition, and cancer drugs offer a prime example.
"If we look at the trajectory of incremental benefi ts in survival that new cancer drugs are giving versus the old drugs, we fi nd that the prices are going up far in excess of the benefi ts," Ramsey says. "There are some exceptions, but the value proposition for these drugs is falling a lot."
Even when multiple new drugs for a given condition are available, prices tend to climb, says Ramsey, citing drugs for chronic myeloid leukemia (CML). The price of imatinib (Gleevec; Novartis) continues to rise, to around $100,000 annually in the United States, while newer rivals nilotinib (Tasigna; Novartis) and dasatinib (Sprycel; Bristol-Myers Squibb) cost even more (Blood 2013; 121:4439-42) .
"Gleevec is still a reliable workhorse in CML," Newcomer comments. "There are now several new drugs that offer a 1% advance in overall survival over Gleevec, yet their pricing can be three to four times as high."
In response, drug companies emphasize the improved therapies being delivered and the massive investments required to bring therapies from laboratory discovery through clinical trials to FDA approval.
Analyses vary tremendously, but one common estimate is that the cost per approved drug exceeds $1 billion. (This fi gure often has been extrapolated from a decade-old Tufts Center for the Study of Drug Development study [J Health Econ 2003; 22:151-85] .)
Given the high risks and large resources inherent in drug development, investors want good paybacks for the drug candidates that do succeed.
Additionally, the push into personalized medicine that targets ever-more-specifi c subpopulations of cancer patients may further boost drug prices, because prices generally rise for products that offer particularly high benefi ts for well-defi ned small groups.
The dramatic advances in treatment that extend survival and improve quality of life for cancer patients don't come cheap. Key among trends that will accelerate costs will be the expanded adoption of often highly expensive molecularly targeted medicines and the companion diagnostics they require, the increased use of therapies in sequence and combination, and the introduction of innovative therapies, such as autologous T-cell treatments, that may be costly to manufacture.
On the upside, oncologists have high hopes that as major cancer biologic drugs go off patent, the advent of biosimilars (generic versions of biologic drugs) expected in the next few years will tend to moderate costs. Some companies with cancer biosimilars in the works have suggested, however, that given the overall U.S. market environment for cancer drugs, the prices they plan for their products will be much closer to prices of the branded products than what is generally seen for generic drugs for other diseases.
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NEWS IN DEPTH
"We price our medicines in consideration of the value they bring to patients and society," says Novartis. "Other important contributing factors include the signifi cant investment in research, the scientifi c innovation the product represents, the growing cost of operating at the highest standards, the level of unmet medical need, and the clinical value that the drug delivers to patients. We work together with government healthcare systems, charities, and other payers to build successful cost-sharing models."
CONTAINING COSTS
Although oncologists can't control drug pricing, they can optimize drug use.
As a fi rst step, "we need to get smarter and smarter about who needs which medicine," comments Amy Abernethy, MD, PhD, associate professor of medicine and director of the cancer care research program at Duke University School of Medicine. "We need to work hard to make sure that companion diagnostic assays are available to us," she says, although their development and use often face tough scientifi c, regulatory, and economic challenges.
Secondly, Abernethy says, it's important to assess when not to give drugs. "When do we continue with successive lines of therapy in a person whose disease has progressed or recurred?" she asks. "Unless we sit down with patients and really understand what they want, often we just keep prescribing. And until we force ourselves to have the hard conversations as a community, it's hard to have that conversation in the room with patients."
Moreover, as treatment options grow ever more complex, decision support systems "will have to tell you at the point of care, here's the smartest solution for this patient right now, and here's what it will cost," she predicts.
The FDA and the Centers for Medicare and Medicaid Services don't systematically gather data for cost-effectiveness studies, but insurers such as UnitedHealthcare do. Similarly, the American Society for Clinical Oncology's CancerLinQ project eventually will include billing data that can be plugged into cost-effectiveness analyses, notes Abernethy, who chairs the CancerLinQ advisory board.
LOOKING FOR GOOD VALUES
As the U.S. healthcare system struggles to broaden coverage and focus away from fee-based payments to outcome-based payments with the implementation of the Affordable Care Act, it needs to address issues such as cost-effectiveness for cancer therapies, oncologists say.
With new melanoma treatments, for example, "the science is exquisite, the potential is audacious, and the costs are remarkably high," says Abernethy. "The other side of that story is, how do we derive value? As a society, we'll have to start to fi gure how we can get our heads around the issues of costs."
Going forward, manufacturers will need to price drugs more directly on their value, says Bruce Booth, PhD, life sciences partner at Atlas Venture in Cambridge, MA. "If a drug provides a real clinical benefi t, it should command premium pricing," he says. "Adding a month or two of life extension isn't clinically meaningful and shouldn't command those premium prices." "Purchasers, particularly the federal government, need to look at the value the drug is providing, and to be able to negotiate based on the value, which would give the manufacturers the right incentives for pricing," says Ramsey. "I'm frankly a little bit pessimistic that this will change soon."
He and Newcomer agree, however, that cancer drug costs offer just one dramatic example of soaring healthcare costs that can't continue in the long run.
More generally, Newcomer points to one economic model suggesting that unless the United States alters its course, by 2018 the total of out-of-pocket expenses and healthcare premiums for a family will be equal to about half of all U.S. household income, which is simply not sustainable (Ann Fam Med 2012; 10:156-62) .
"Drastic change is coming," says Newcomer. "What that looks like is anyone's guess, but what's clear is that the status quo just can't be maintained."
As one effect, "developers will need to have as much emphasis on making new drugs affordable as they do on making new drugs available," he adds.
"We're developing novel agents with novel mechanisms each year, and these drugs are expensive to develop and to produce," says Duke's Zafar. "But I wonder about the margin between the expense of drug production and the marketing price. We really have to consider whether that model is sustainable going forward, particularly since our healthcare costs are rising faster than in any other country in the world."
"From the start of drug development to large postmarketing studies, cost will have to be considered every step of the way," Zafar emphasizes. "We'll all have to learn the language of cost and cost-effectiveness to understand how it impacts our industry, our healthcare system, and, most importantly, our patients."-Eric Bender ■ In covering cancer drug costs, the U.S. approach stands in stark contrast to that of many other developed nations (Blood 2013; 121:4439-42) .
In the UK, the National Health Service's National Institute for Health and Care Excellence (NICE) negotiates pricing for some new drugs with manufacturers, which explains why the chronic myeloid leukemia kinase inhibitors dasatinib, imatinib, and nilotinib cost about a third what they do in the United States.
In addition, NICE flatly rejects drugs deemed to offer insufficient benefit for the price.
The UK continues to push on drug pricing, with NICE scheduled to implement a blueprint for "value-based" pricing of new drugs in 2014. In June, the UK's Department of Health announced that it would seek to cut pricing on many existing branded drugs by 10% to 20%. 
